Is Teva Pharma Stock a Good Investment?
Teva Pharma Investment Advice | TEVA |
- Examine Teva Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Teva Pharma's leadership team and their track record. Good management can help Teva Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Teva Pharma's business and its evolving consumer preferences.
- Compare Teva Pharma's performance and market position to its competitors. Analyze how Teva Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if Teva Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Teva Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Teva Pharma Industries stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Teva Pharma Industries is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Teva Pharma Stock
Researching Teva Pharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 57.0% of the company shares are owned by institutional investors. The book value of Teva Pharma was at this time reported as 5.35. The company has Price/Earnings To Growth (PEG) ratio of 1.29. Teva Pharma Industries recorded a loss per share of 0.85. The entity last dividend was issued on the 27th of November 2017. The firm had 2:1 split on the 1st of July 2004.
To determine if Teva Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Teva Pharma's research are outlined below:
| Teva Pharma generated a negative expected return over the last 90 days | |
| Teva Pharma Industries currently holds 20.15 B in liabilities with Debt to Equity (D/E) ratio of 2.27, implying the company greatly relies on financing operations through barrowing. Teva Pharma Industries has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Teva Pharma's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 15.85 B. Net Loss for the year was (615 M) with profit before overhead, payroll, taxes, and interest of 6.97 B. | |
| Teva Pharma has a strong financial position based on the latest SEC filings | |
| About 57.0% of Teva Pharma shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Tacrolimus Market Expected To Reach USD 10823.72 Million by 2032, with a CAGR of 5.65 percent Introspective Market Research |
Teva Pharma Quarterly Good Will |
|
Teva Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Teva Pharma Industries. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Teva Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 31st of January 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 31st of January 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Teva Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Teva Pharma's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2001-04-24 | 2001-03-31 | 0.09 | 0.1 | 0.01 | 11 | ||
2000-05-04 | 2000-03-31 | 0.07 | 0.08 | 0.01 | 14 | ||
1998-05-11 | 1998-03-31 | 0.06 | 0.05 | -0.01 | 16 | ||
1998-02-24 | 1997-12-31 | 0.05 | 0.04 | -0.01 | 20 | ||
1996-11-11 | 1996-09-30 | 0.04 | 0.05 | 0.01 | 25 | ||
2002-04-29 | 2002-03-31 | 0.14 | 0.16 | 0.02 | 14 | ||
2002-02-14 | 2001-12-31 | 0.15 | 0.17 | 0.02 | 13 | ||
1996-08-15 | 1996-06-30 | 0.05 | 0.03 | -0.02 | 40 |
Know Teva Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Teva Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Teva Pharma Industries backward and forwards among themselves. Teva Pharma's institutional investor refers to the entity that pools money to purchase Teva Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Slate Path Capital Lp | 2024-09-30 | 13.7 M | Millennium Management Llc | 2024-06-30 | 12.1 M | Pointstate Capital Lp | 2024-09-30 | 9.8 M | Geode Capital Management, Llc | 2024-09-30 | 8.8 M | Glenview Capital Management Llc | 2024-09-30 | 8.5 M | Renaissance Technologies Corp | 2024-09-30 | 8.1 M | Australiansuper Pty Ltd | 2024-09-30 | 7.9 M | Viking Global Investors Lp | 2024-09-30 | 7.6 M | Parsifal Capital Management, Lp | 2024-09-30 | 6.2 M | Fmr Inc | 2024-09-30 | 62.7 M | Blackrock Inc | 2024-06-30 | 43 M |
Teva Pharma's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 18.8 B.Market Cap |
|
Teva Pharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | 0.01 | 0.01 | |
| Return On Assets | (0.01) | (0.01) | |
| Return On Equity | (0.07) | (0.07) |
Determining Teva Pharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Teva Pharma is a good buy. For example, gross profit margin measures Teva Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Teva Pharma's profitability and make more informed investment decisions.
Teva Pharma's Earnings Breakdown by Geography
Please note, the presentation of Teva Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Teva Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Teva Pharma's management manipulating its earnings.
Evaluate Teva Pharma's management efficiency
Teva Pharma Industries has return on total asset (ROA) of 0.0556 % which means that it generated a profit of $0.0556 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1752) %, meaning that it created substantial loss on money invested by shareholders. Teva Pharma's management efficiency ratios could be used to measure how well Teva Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.03. In addition to that, Return On Capital Employed is expected to decline to 0.01. At present, Teva Pharma's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 3.42, whereas Total Assets are forecasted to decline to about 26.4 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.26 | 8.49 | |
| Tangible Book Value Per Share | (12.90) | (12.26) | |
| Enterprise Value Over EBITDA | 18.22 | 14.50 | |
| Price Book Value Ratio | 1.56 | 1.48 | |
| Enterprise Value Multiple | 18.22 | 14.50 | |
| Price Fair Value | 1.56 | 1.48 | |
| Enterprise Value | 38.6 B | 40.5 B |
The leadership approach at Teva Pharma's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta 0.868 |
Basic technical analysis of Teva Stock
As of the 28th of November, Teva Pharma has the Variance of 3.14, coefficient of variation of (1,125), and Risk Adjusted Performance of (0.06). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Teva Pharma Industries, as well as the relationship between them.Teva Pharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Teva Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Teva Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Teva Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Shalev Varda over two months ago Disposition of 12872 shares by Shalev Varda of Teva Pharma subject to Rule 16b-3 | ||
Hughes Eric A over three months ago Disposition of 45060 shares by Hughes Eric A of Teva Pharma at 17.3762 subject to Rule 16b-3 | ||
Sol Barer over three months ago Disposition of 37598 shares by Sol Barer of Teva Pharma subject to Rule 16b-3 | ||
Mark Sabag over six months ago Disposition of 100000 shares by Mark Sabag of Teva Pharma at 13.5209 subject to Rule 16b-3 | ||
Janet Vergis over a year ago Exercise or conversion by Janet Vergis of 15810 shares of Teva Pharma subject to Rule 16b-3 | ||
David Stark over a year ago Exercise or conversion by David Stark of 18430 shares of Teva Pharma subject to Rule 16b-3 |
Teva Pharma's Outstanding Corporate Bonds
Teva Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Teva Pharma Industries uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Teva bonds can be classified according to their maturity, which is the date when Teva Pharma Industries has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| TEVA 5125 09 MAY 29 Corp BondUS88167AAQ40 | View | |
| TEVA 475 09 MAY 27 Corp BondUS88167AAP66 | View | |
| US88167AAN19 Corp BondUS88167AAN19 | View | |
| TEVA 8125 15 SEP 31 Corp BondUS88167AAR23 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| TEXACO CAP INC Corp BondUS881685BB68 | View | |
| US881685AX97 Corp BondUS881685AX97 | View |
Understand Teva Pharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Teva Pharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | 0.4766 | |||
| Mean Deviation | 1.34 | |||
| Coefficient Of Variation | (1,125) | |||
| Standard Deviation | 1.77 | |||
| Variance | 3.14 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.45) | |||
| Treynor Ratio | 0.4666 | |||
| Maximum Drawdown | 12.42 | |||
| Value At Risk | (2.23) | |||
| Potential Upside | 2.51 | |||
| Skewness | (0.36) | |||
| Kurtosis | 3.38 |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | 0.4766 | |||
| Mean Deviation | 1.34 | |||
| Coefficient Of Variation | (1,125) | |||
| Standard Deviation | 1.77 | |||
| Variance | 3.14 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.45) | |||
| Treynor Ratio | 0.4666 | |||
| Maximum Drawdown | 12.42 | |||
| Value At Risk | (2.23) | |||
| Potential Upside | 2.51 | |||
| Skewness | (0.36) | |||
| Kurtosis | 3.38 |
Consider Teva Pharma's intraday indicators
Teva Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Teva Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 139889.0 | |||
| Daily Balance Of Power | (0.08) | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 16.57 | |||
| Day Typical Price | 16.57 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.02) | |||
| Relative Strength Index | 36.25 |
Teva Pharma Corporate Filings
F4 | 21st of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 5th of August 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Teva Stock media impact
Far too much social signal, news, headlines, and media speculation about Teva Pharma that are available to investors today. That information is available publicly through Teva media outlets and privately through word of mouth or via Teva internal channels. However, regardless of the origin, that massive amount of Teva data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Teva Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Teva Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Teva Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Teva Pharma alpha.
Teva Pharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Teva Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Teva Pharma Industries Historical Investor Sentiment
Investor biases related to Teva Pharma's public news can be used to forecast risks associated with an investment in Teva. The trend in average sentiment can be used to explain how an investor holding Teva can time the market purely based on public headlines and social activities around Teva Pharma Industries. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Teva Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Teva Pharma and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Teva Pharma news discussions. The higher the estimate score, the more favorable the investor's outlook on Teva Pharma.
Teva Pharma Corporate Directors
| Nechemia Peres | Independent Director | Profile | |
| JeanMichel Halfon | Statutory - independent director | Profile | |
| Perry Nisen | Independent Director | Profile | |
| Gerald Lieberman | Independent Director | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (0.85) | Revenue Per Share 14.879 | Quarterly Revenue Growth 0.125 | Return On Assets 0.0556 |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Teva Pharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.